【摘要】：目的探討腦得康治療進展性腦卒中(PIS)的臨床療效及對炎性因子血清學(xué)水平的影響。方法 98例PIS患者根據(jù)隨機數(shù)字表法分為對照組和觀察組,各49例,兩組均進行常規(guī)治療,觀察組在此基礎(chǔ)上加用腦得康丸,8 w為1個療程。觀察并對比兩組的臨床療效、神經(jīng)功能缺損程度[美國國立衛(wèi)生研究院腦卒中量表(NIHSS)評分]和日常生活能力[日常生活活動能力量表(ADL)評分]以及血清炎性因子水平。結(jié)果觀察組的臨床效果顯著高于對照組(P0.05)。治療8 w時兩組NIHSS評分均顯著降低,ADL評分均顯著升高且觀察組與對照組相比(P0.05)。治療后4、8 w時觀察組血清白細胞介素(IL)-6、超敏C反應(yīng)蛋白(hs-CRP)水平均顯著低于對照組,血清雌二醇(E2)水平顯著高于對照組(P0.05)。結(jié)論腦得康可改善SIP患者神經(jīng)功能、日常生活能力,抑制血清IL-6、hs-CRP水平并升高血清E2水平,治療效果較好。
[Abstract]:Objective to investigate the clinical efficacy of Naodekang in the treatment of (PIS) in patients with progressive stroke and its effect on the serum level of inflammatory factors. Methods 98 patients with PIS were divided into control group (n = 49) and observation group (n = 49) according to the method of random number table. All patients in the two groups were treated with routine therapy. On this basis, the observation group was given Naokang pills for 8 weeks as a course of treatment. To observe and compare the clinical efficacy, neurological impairment (NIHSS) score of NIH Stroke scale), ADL (activity of Daily living scale (ADL) score) and serum inflammatory factor level between the two groups. Results the clinical effect of the observation group was significantly higher than that of the control group (P0.05). At the 8th week after treatment, the NIHSS scores of the two groups were significantly decreased, the ADL scores were significantly increased, and the observation group was compared with the control group (P0.05). The levels of serum interleukin-6 (IL)-6) and hypersensitive C-reactive protein (hs-CRP) in the observation group were significantly lower than those in the control group at the 4th and 8th week after treatment, and the serum estradiol (E2) level was significantly higher than that in the control group (P0.05). Conclusion Naodekang can improve the neurological function, activity of daily living (ADL), inhibit the level of serum IL-6,hs-CRP and increase the level of serum E _ 2 in patients with SIP. The therapeutic effect is better.
【作者單位】： 膠州市人民醫(yī)院神經(jīng)外二科;
【基金】：青島市衛(wèi)生科技指導(dǎo)項目(2015WJZD145)
【分類號】：R743.3

【相似文獻】

相關(guān)期刊論文 前10條

1 李建英;楊春水;楊志剛;林勤郁;李雯飛;金明月;;急性腦梗死患者多項血清炎性因子及血流動力學(xué)指標研究[J];海南醫(yī)學(xué)院學(xué)報;2012年11期

2 李強;;調(diào)脂治療對急性腦梗死患者血清炎性因子水平的影響[J];中華老年心腦血管病雜志;2011年09期

3 沈麗華;葉民;丁新生;韓秋;吳二兵;;大鼠腦缺血再灌注后全腦及血清炎性因子水平研究[J];中風(fēng)與神經(jīng)疾病雜志;2009年04期

4 李強;;大劑量阿托伐他汀對急性腦梗死患者血清炎性因子的影響[J];山東醫(yī)藥;2011年25期

5 王光勝;王元偉;陳孝東;楊同慧;常春紅;吳樂懷;顧漢沛;;急性腦梗死患者血清炎性因子的變化及其與近期預(yù)后的關(guān)系[J];中華老年心腦血管病雜志;2011年06期

6 劉真;;抗氧化治療對急性期腦梗死血清炎性因子的影響[J];中國煤炭工業(yè)醫(yī)學(xué)雜志;2010年06期

7 馮納婷;李新立;張曉名;劉群才;;不同時間正壓通氣對腦出血并呼吸衰竭患者血清炎性因子水平的影響[J];實用醫(yī)藥雜志;2011年08期

8 馬征;孫雅菲;康玲伶;房銘輝;高燕軍;;急性腦出血患者血清炎性因子和氧化應(yīng)激產(chǎn)物的動態(tài)監(jiān)測及臨床意義[J];河北醫(yī)藥;2014年11期

9 陳澤峰;王洪新;董銀華;;抗氧化治療對急性期腦梗死血清炎性因子的影響[J];臨床薈萃;2010年04期

10 陳晶;王萍;許波;徐輝;;早期心理干預(yù)對急性腦梗死抑郁狀態(tài)及血清炎性因子水平影響[J];青島大學(xué)醫(yī)學(xué)院學(xué)報;2014年06期

相關(guān)碩士學(xué)位論文 前1條

1 宋新劍;加味補陽還五湯配合現(xiàn)代康復(fù)對中風(fēng)后疲勞患者血清炎性因子的影響[D];廣州中醫(yī)藥大學(xué);2011年

，

本文編號：2463162